On Board the Cell Shuttle with Cellares' Fabian Gerlinghaus
Listen now
Description
Having raised $82 million in its latest funding round, tech firm Cellares Corporation is looking to advance development of its cell therapy manufacturing platform, the Cell Shuttle.   We spoke with co-founder and CEO Fabian Gerlinghaus about the current limitations in CAR-T production and how the Cell Shuttles’ scalable, modular, and automated nature could be a gamechanger in the burgeoning space   Keep up with BioProcess Insider on our website. Follow us on LinkedIn and Twitter: @BioProInsider @BioProcessIntl @Dan5tanton  
More Episodes
MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts. This episode of our regular podcast Voices of Biotech  brings you an in-depth conversation with Jeffrey Whitford, vice president of sustainability and social...
Published 04/08/24
Samsung Biologics' James Choi discusses the CDMO’s role in teaming up with Big Pharma to tackle sustainability in the biotech space.    This episode of the Voices of Biotech – brought to you by the BioProcess Insider Expression Platform – brings you an interesting conversation with Choi about the...
Published 03/18/24